{"transactions":[{"id":2251509,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:04:29.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":95916,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2029-09-05","underlying":"Common Stock","underlying_shares":95916},"source":{"system":"sec-edgar","filing":"0000899243-22-020081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322020081/doc4.xml","form_type":"4"}},{"id":2251508,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:04:29.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":150818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":150818},"source":{"system":"sec-edgar","filing":"0000899243-22-020081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322020081/doc4.xml","form_type":"4"}},{"id":2251507,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:04:29.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":27300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":5.09,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":27300},"source":{"system":"sec-edgar","filing":"0000899243-22-020081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322020081/doc4.xml","form_type":"4"}},{"id":2251506,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:04:29.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":101180,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."}],"balance_after":0,"derivative":{"exercise_price":2.05,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":101180},"source":{"system":"sec-edgar","filing":"0000899243-22-020081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322020081/doc4.xml","form_type":"4"}},{"id":2251505,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-31T10:04:29.000Z","date":"2022-05-31","kind":"disposition_to_issuer","acquired":false,"shares":54600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the \"Issuer\"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the \"Merger\"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an \"In the Money Issuer Option\") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":13.5,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":54600},"source":{"system":"sec-edgar","filing":"0000899243-22-020081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322020081/doc4.xml","form_type":"4"}},{"id":2288776,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-28T17:03:37.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":54600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest 25% on the first anniversary of the vesting start date of March 5, 2021 and in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Persons continued service through such date."}],"balance_after":54600,"derivative":{"exercise_price":13.5,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":54600},"source":{"system":"sec-edgar","filing":"0000899243-22-015855","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322015855/doc4.xml","form_type":"4"}},{"id":2421136,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T16:05:25.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":101180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on January 27, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":101180,"derivative":{"exercise_price":2.05,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":101180},"source":{"system":"sec-edgar","filing":"0000899243-22-003631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924322003631/doc4.xml","form_type":"4"}},{"id":2611525,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-06T16:05:24.000Z","date":"2021-08-04","kind":"grant","acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on August 4, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":27300,"derivative":{"exercise_price":5.09,"expiration_date":"2031-08-03","underlying":"Common Stock","underlying_shares":27300},"source":{"system":"sec-edgar","filing":"0000899243-21-031911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924321031911/doc4.xml","form_type":"4"}},{"id":3063557,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-10T18:00:27.000Z","date":"2020-08-06","kind":"grant","acquired":true,"shares":150818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on August 6, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":150818,"derivative":{"exercise_price":15,"expiration_date":"2030-08-05","underlying":"Common Stock","underlying_shares":150818},"source":{"system":"sec-edgar","filing":"0000899243-20-021900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000089924320021900/doc4.xml","form_type":"4"}},{"id":3623363,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-01T17:09:49.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":50200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 28, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":50200,"derivative":{"exercise_price":8.36,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":50200},"source":{"system":"sec-edgar","filing":"0001567619-19-005837","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000156761919005837/doc1.xml","form_type":"4"}},{"id":4040706,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-02-22T18:25:32.000Z","date":"2018-02-20","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":6.31,"expiration_date":"2028-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001140361-18-009668","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000114036118009668/doc1.xml","form_type":"4"}},{"id":4225631,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-08-24T18:04:07.000Z","date":"2017-08-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.1,"expiration_date":"2027-08-21","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-17-033209","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000114036117033209/doc1.xml","form_type":"4"}},{"id":4225630,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":126740,"kind":"person","name":"Wooldridge James","position":1,"cik":"0001710641","reported_name":"Wooldridge James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-08-24T18:04:07.000Z","date":"2017-08-22","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 1/4th of the shares subject to the option on July 10, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":165000,"derivative":{"exercise_price":3.1,"expiration_date":"2027-08-21","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001140361-17-033209","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710641/000114036117033209/doc1.xml","form_type":"4"}}]}